1250397-72-8 Usage
Uses
Used in Pharmaceutical Industry:
2,3-difluoro-N-methyl-benzamide is used as a building block for the synthesis of biologically active compounds, primarily due to its unique structure and functional groups. It is particularly valuable in the development of new drugs, where its properties can be leveraged to enhance the efficacy and selectivity of pharmaceutical agents.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 2,3-difluoro-N-methyl-benzamide is utilized as a precursor in the creation of pesticides. Its chemical properties make it suitable for the design of compounds that can effectively control pests and diseases in agriculture, potentially increasing crop yields and reducing losses.
Used in Organic Synthesis:
2,3-difluoro-N-methyl-benzamide is also used as an important intermediate in organic synthesis. Its presence in various chemical reactions can lead to the formation of a wide range of complex organic molecules, contributing to the advancement of chemical research and the development of novel materials and compounds.
Potential Therapeutic Uses:
While further research is required, 2,3-difluoro-N-methyl-benzamide may have biological activity and potential therapeutic uses. Its unique structure could offer new avenues for treating diseases and conditions that are currently challenging to address with existing pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1250397-72-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,0,3,9 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1250397-72:
(9*1)+(8*2)+(7*5)+(6*0)+(5*3)+(4*9)+(3*7)+(2*7)+(1*2)=148
148 % 10 = 8
So 1250397-72-8 is a valid CAS Registry Number.
1250397-72-8Relevant academic research and scientific papers
SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
-
, (2011/06/16)
An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.
